IQVIA (NYSE:IQV) Price Target Raised to $288.00 at JPMorgan Chase & Co.

IQVIA (NYSE:IQV) had its price objective boosted by JPMorgan Chase & Co. from $260.00 to $288.00 in a report released on Monday, Benzinga reports. The brokerage currently has an overweight rating on the medical research company’s stock.

A number of other equities research analysts have also weighed in on the stock. Evercore ISI boosted their target price on shares of IQVIA from $230.00 to $270.00 and gave the company an outperform rating in a research note on Tuesday, July 23rd. Argus upgraded IQVIA to a strong-buy rating in a research report on Wednesday, July 31st. The Goldman Sachs Group initiated coverage on IQVIA in a research report on Thursday, June 6th. They issued a buy rating and a $270.00 target price on the stock. Jefferies Financial Group lowered shares of IQVIA from a buy rating to a hold rating and reduced their price target for the company from $266.00 to $242.00 in a research report on Wednesday, July 24th. Finally, Robert W. Baird raised their price objective on shares of IQVIA from $235.00 to $251.00 and gave the stock a neutral rating in a report on Tuesday, July 23rd. Five equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average target price of $265.67.

IQVIA Stock Up 2.8 %

IQV stock opened at $236.07 on Monday. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. IQVIA has a 1-year low of $167.42 and a 1-year high of $261.73. The stock has a market capitalization of $43.01 billion, a P/E ratio of 32.25, a P/E/G ratio of 2.28 and a beta of 1.49. The business has a fifty day moving average price of $222.43 and a 200-day moving average price of $230.96.

IQVIA (NYSE:IQV) last issued its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. The business had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. IQVIA’s revenue was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.22 EPS. Equities analysts forecast that IQVIA will post 10.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On IQVIA

A number of hedge funds have recently made changes to their positions in IQV. Versant Capital Management Inc lifted its holdings in IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after purchasing an additional 110 shares in the last quarter. Opal Wealth Advisors LLC purchased a new position in shares of IQVIA in the second quarter worth $27,000. Rise Advisors LLC bought a new position in shares of IQVIA during the first quarter worth $31,000. Riverview Trust Co purchased a new position in IQVIA during the first quarter valued at $32,000. Finally, International Assets Investment Management LLC bought a new stake in IQVIA in the 2nd quarter valued at $32,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.